Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company enters licencing agreement with Canadian leader

Shares have rallied 15% intra-day, currently priced at $0.85.
concept for medical cannabis
To date, NAC has helped more than 10,000 Canadian medicinal cannabis patients

The Hydroponics Company Ltd (ASX:THC) has reached a licensing agreement with National Access Cannabis (NAC) of Canada.

The agreement gives THC immediate access to NAC’s intellectual property that will assist in the development of a professional clinic model, offering THC a unique path to market in Australia.

NAC is Canada’s best practices leader in delivering secure, safe, and responsible access to legal medicinal cannabis.

It provides high-quality physician and patient support and training in professional patient-friendly clinics environments.

THC will use the Canadian clinical model to create a solution in Australia

David Radford, chief executive, said: “Having visited their medical clinic in Ottawa, I believe that the quality processes and care that they have developed for their patients has a real and exciting place in the Australian marketplace.

“We will be working with the State Governments and Physicians to rapidly integrate this unique, quality assured program for the betterment of the Australian patients.

READ: The Hydroponics Company in company making partnership with Israel's BOL Pharma

“We look forward to working with the NAC team and leveraging their clinical model to provide a local healthcare solution which will facilitate patient access to a broad range of high, quality, legal medicinal cannabis products in Australia and New Zealand.

“Our expansion into the development of medicinal cannabis clinics will allow THC to work with local cannabis companies as they seek to develop a path to market.”

10-year licence in Australia and New Zealand with Asia option

The agreement provides for a transfer of technology, knowledge and intellectual property for 10 years in Australia and New Zealand, with a further option to extend by 10 years.

It also provides for a first right of refusal option to develop into Asia as the market matures.

THC is able to leverage NAC’s extensive relationships with Canadian licenced producers and access to new medicinal products.

THC will pay NAC a licensing fee of $500,000 upon or before the second anniversary of the agreement or successfully achieving an initial gross revenue milestone of $1 million, whichever occurs first.

Thereafter, THC will pay NAC ongoing quarterly royalties equivalent to 7.5% of gross revenue.

View full THC profile View Profile

The Hydroponics Company Timeline

Related Articles

People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use